U.S. Markets closed

InflaRx shares plummet over 90% after drug test failure

InflaRx shares plummet over 90% after the biotech company said its drug for an inflammatory skin disorder failed to show a show a significant response compared to a placebo. The drug, called IFX-1, is also being tested to treat other skin conditions. Yahoo Finance's Jared Blikre joins Seana Smith.